IL17A and nervous system disorder: Their result showed that CAQK-modified nanoparticles successfully delivered therapeutic agents into the site of spinal cord injury and inhibited the activation of astrocytes due to the reduction of interleukin-17 and interleukin-17-related inflammatory factors.11 Targeted drug delivery to reactive astrocytes in neurological disorders can be an approach to control the progress of the disease.